This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology (ALGN) Launches New Features in iTero Family
by Zacks Equity Research
Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Baxter (BAX) Unveils New Digital Health Module for PD Patients
by Zacks Equity Research
Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
Why Is Henry Schein (HSIC) Down 4.4% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
by Zacks Equity Research
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
HSIC vs. SAUHF: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. SAUHF: Which Stock Is the Better Value Option?
Henry Schein (HSIC) Clinches HHS Deal for COVID-19 Supplies
by Zacks Equity Research
Henry Schein (HSIC) to extend effective inventory management and extensive logistical support for PPE and COVID related products within the spectrum of U.S. health care.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both its segments.
Medtronic's (MDT) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fourth-quarter results reflect a strong recovery in terms of elective procedures.
Here's Why You Should Buy Henry Schein (HSIC) Stock Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) on solid first-quarter performance and strategic deals.
HSIC vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. CNMD: Which Stock Is the Better Value Option?
Henry Schein (HSIC) Software Module to Enhance Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) latest software module is expected to provide better patient care and improved patient experience.
Henry Schein's (HSIC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Henry Schein, Inc. (HSIC).
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Henry Schein (HSIC) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Henry Schein (HSIC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Henry Schein (HSIC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 49.40% and 3.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HSIC vs. SAUHF: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. SAUHF: Which Stock Is the Better Value Option?
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.
5 MedTech Outperformers With Nearly 40% or More Gain in 2021
by Debanjana Dey
Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.